Synlogic Discontinues Development of SYNB1020 to Treat Hyperammonemia
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/19/2026
- Tech selloff weighs down Wall Street as bond yields climb
- Baidu slips as Q2 results miss estimates despite growth in AI cloud business
- Nvidia or Sandisk? BofA reveals which stock is under-owned and which is crowded
- Home Depot beats estimates, reaffirms fiscal 2026 guidance
- Citi says positioning risk is shifting from short squeezes to profit-taking
- Tech selloff weighs down Wall Street as bond yields climb
- Francisco Partners to acquire Weave Communications for $650M
- Nvidia or Sandisk? BofA reveals which stock is under-owned and which is crowded
- Lowe's Cos. (LOW) Tops Q2 EPS by 17c, Misses on Revenue; Offers Fy27 Guidance
- Goldman Sachs to acquire real estate company LCN for up to $410M
Synlogic Inc. (SYBX) PT Lowered to $14 at Wedbush
August 21, 2019 4:16 AM EDTWedbush analyst David Nierengarten lowered the price target on Synlogic Inc. (NASDAQ: SYBX) to $14.00 (from $20.00) while maintaining a Outperform rating.
... MoreSynlogic Inc. (SYBX) PT Lowered to $6 at Jefferies
August 21, 2019 4:16 AM EDTJefferies analyst Chris Howerton lowered the price target on Synlogic Inc. (NASDAQ: SYBX) to $6.00 (from $18.00) while maintaining a Buy rating.
The analyst comments "After failing to show the efficacy of '1020 in patients, SYBX announced today that it will discontinue... More
